Ebola

As sporadic cases of Ebola continue to arise in West Africa, a controversial approach could be utilized to increase survival rates in those who are infected.

A new study conducted by an Ebola diagnostic laboratory in Liberia has found that there is a connection between the survival of individuals with Ebola and co-infection with Plasmodium parasites that cause malaria.

The first household survey was conducted in Liberia to examine the collateral harm to maternal healthcare delivery services in areas impacted by the Ebola epidemic. It showed that since the Ebola epidemic began, facility-based deliveries have declined mostly due to fear of acquiring infection, keeping women away from using the healthcare services available to them.

CDC Public Health Response Director Warns Lack of Funds Hampers Protection Efforts

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response, at the Centers for Disease Control and Prevention explains what they learned from handling the response to the Ebola outbreak in 2014-2015.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response at the Centers for Disease Control and Prevention (CDC) explains what the CDC learned from responding to the Ebola outbreak and how this has impacted the response to the Zika virus.

Those patients who survive infections caused by the Ebola or Marburg viruses may gain at least partial immunity to other filoviruses through specific antibodies generated during serological immune responses.

A new study may uncover the mystery behind why the Ebola virus disease is fatal to only some, and lead to pathways to new treatments.

The FDA recently granted Emergency Use Authorization for the Idylla Ebola Virus Triage Test, a diagnostic test which detects the presence of the virus in blood.

“An outbreak anywhere is a risk everywhere,” according to the Centers for Disease Control and Prevention (CDC). Officers of the CDC’s Epidemic Intelligence Service (EIS) are studying several emerging infections – those that have recently increased or show signs of increasing soon – and five researchers presented their results May 4 in the Emerging Infections session of the 65th Annual Epidemic Intelligence Service (EIS) Conference in Atlanta, Georgia.

Taking a page out of U.S. Biodefense practices may be the first step in preparing for future infectious disease outbreaks.

A recent case study adds to a small, but disturbing collection of reports describing the transmission of Ebola virus from mother to child through breastfeeding.

Recent Ebola-linked deaths in Guinea caused the World Health Organization (WHO) Guinea office to implement a “ring vaccination” strategy in which it administered an experimental Ebola vaccine on 800 of 1000 suspected cases, including 182 suspected at high-risk.

The Obama administration recently announced plans to shift nearly $600 million in funds designated to battle the Ebola epidemic toward the fight against Zika.

A Guinea child who was previously diagnosed with Ebola has succumbed to death and another Koropara civilian died after traveling to a neighboring village.

After three unexplained deaths in Koropara, a small village in southern Guinea, WHO diagnosed two individuals with Ebola.

Two investigational vaccines showed promise to protect against Ebola virus disease, according to data from the phase 2 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL 1) trial.

Researchers from the National Institutes of Health found that PCR-based testing is the most effective diagnostic test to assist with case-patient management during Ebola virus outbreaks in malaria-endemic areas.

Current epidemic response procedures may change due to the finding that the Ebola virus can persist in wastewater longer than previously believed.

Research has shown that Ebola virus disease (EVD) not only has the power to survive on plastic surfaces and spread through sexual transmission, the disease has also proven to last in another place.

The US Department of Health and Human Services (HHS) plans to spend $2.7 billion in emergency funds to counter the spread of Ebola. Spending categories range from over a half billion dollars for international projects to a half million dollars for regulatory work that includes monitoring for fraudulent Ebola products.

Now that the two American patients infected with Ebola have arrived safely in Atlanta, the US Centers for Disease Control and Prevention has released more information about ZMapp, the experimental medication the patients were treated with before being flown back to the US.

While hundreds of people have died in Africa from the latest outbreak of the Ebola virus, two infected Americans appear to be recovering after receiving doses of an experimental serum that has never been tested in human subjects